P184 Pooled Week 96 efficacy and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV;TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults (Poster not yet available)
C Orkin¹, C Cohen², J-M Molina³, I Cassetti⁴, P Chetchotisakd⁵, A Lazzarin⁶, F Rhame⁷, HJ Stellbrink⁸, L Taisheng⁹, H Crauwels¹⁰, L Rimsky¹⁰, S Vanveggel¹⁰, P Williams¹⁰ and K Boven^11
1Barts and The London NHS Trust, London, UK, ²Community Research Initiative of New England, Boston, MA, USA, ³Department of Infectious Diseases, Paris, France, ⁴Helios Salud, Buenos Aires, Argentina, ⁵Faculty of Medicine, Khon Kaen, Thailand, ⁶Vita-Salute, San Raffaele University, Milan, Italy, ⁷Abbott Northwestern Hospital, Minneapolis, MN, USA, ⁸ICH Study Center, Hamburg, Germany, ⁹Department of Infectious Diseases, PUMCH, Beijing, China, ¹⁰Janssen Infectious Diseases BVBA, Beerse, Belgium, ¹¹Janssen Research & Development, LLC, Titusville, NJ, USA

P185 Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) in antiretroviral-naïve subjects: 96-week safety and efficacy results of the PROGRESS study
R Trinh¹, J Gathe², J Reynes³, F Pulido⁴, M Tian¹, L Fredrick¹, T Podsadecki¹, M Norton¹ and A Nilius^1
1Abbott, Abbott Park, IL, USA, ²Therapeutic Concepts, Houston, TX, USA, ³Montpellier University Hospital, Montpellier, France, ⁴Unidad VIH. Hospital Universitario 12 de Octubre, Madrid, Spain

P186 Virologic suppression is maintained in virologically suppressed HIV-1 infected subjects switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) single-tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir (FTC/RPV/TDF) STR: week-24 results of GS-111 (Poster not yet available)
A Mills¹, C Cohen², E DeJesus³, C Brinson⁴, K Yale⁵, S Ramanathan⁵, R Ebrahim⁵, S Chuck⁵ and A Cheng^5
1Anthony Mills MD Inc, Los Angeles, CA, ²Community Research Initiative, Boston, MA, ³Orlando Immunology Center, Orlando, CA, ⁴Capital Medical Associates, Washington, DC, ⁵Gilead Sciences, Foster City, CA

P187 Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naïve HIV-infected adults with £100,000 c/mL baseline viral load (Poster not yet available)
K White¹, V Van Eygen², J Vingerhoets², K Boven³, G Picchio³, R Quercia⁴, S Chuck¹ and L Rimsky^2
1Gilead Sciences, Inc., Foster City, CA, USA, ²Tibotec BVBA, Beerse, Belgium, ³Janssen R&D, Titusville, NJ, USA, ⁴Gilead Sciences, Inc., Stockley Park, UK

P188 Ineffective central nervous system penetration of maraviroc(MVC) and ritonavir boosted darunavir(DRV/r) dual therapy (Poster not yet available)
C Okoli, N Ahmed and J Ainsworth
North Middlesex University Hospital, London, UK

P189 Outcomes of protease inhibitor Darunavir / Ritonavir (DRV/r) monotherapy in a clinical setting
R Castles¹, C Pacho², J Swan¹, S Sonecha¹ and M Nelson^1
1Chelsea and Westminster NHS Foundation Trust, London, UK, ²Sant Pau University Hospital, Barcelona, Spain

P190 The utility of resistance testing in the clinical management of HIV-1 infection
D Bonsall, D Bradshaw, S Mandalia and M Nelson
Imperial College London, London, UK

P191 Cost effectiveness of rilpivirine- or efavirenz-based regimens for treatment-naïve, HIV-1-infected patients: NHS England and Wales perspective
I Girod¹, M Bell³, I Adriaenssen² and C Knight^3
1Janssen, High Wycombe, UK, ²Janssen Global Services, Beerse, Belgium, ³RTI Health Solutions, Manchester, UK

P192 Five-year follow up of safety and efficacy of Truvada Or Kivexa in combination with Efavirenz in Treatment Naïve HIV patients – Multicenter prospective cohort study (Poster not yet available)
S Das¹, J Arumainayagam², E Carlin³, K Bilakanti¹, L Riddle⁴, M Pammi³, S Chandramani², I Ahmed-Jushuf³ and M Ghanem^4
1Coventry & Warwickshire Partnership Trust, Coventry, UK, ²Walsall Manor Hospital, Walsall, UK, ³Nottingham University Hospital, Nottingham, UK, ⁴Northamptonshire Healthcare NHS Trust, Northampton, UK

P193 Protease inhibitor-based dual antiretroviral therapy (PIDAT) in clinical practice (Poster not yet available)
N Marshall¹, C Smith², L Swaden¹, M Tyrer¹ and M Johnson^1
1Royal Free Hospital NHS Trust, London, UK, ²University College London, London, UK

P194 Is dual therapy the new triple therapy? An audit of maraviroc (MVC) and ritonavir boosted darunavir (DRV/r) in treatment experienced patients (Poster not yet available)
N Ahmed, C Okoli and J Ainsworth
North Middlesex University Hospital, London, UK

P195 Switching to atazanavir due to therapeutic tenders: short term outcomes
N Marshall¹, C Smith², L Swaden¹ and M Johnson^1
1Royal Free NHS Trust, London, UK, ²University College London, London, UK

P196 The use of Enfuvirtide in acutely unwell patients (Poster not yet available)
M Evans and E Wilkins
North Manchester General Hospital, Manchester, UK

P197 Safety, tolerability, and efficacy of lopinavir/ritonavir (LPV/r) in HIV-infected women: meta-analysis of 7 randomized clinical trials (RCTs) through 48 weeks
R Trinh, A Hermes, L Fredrick, M Pasley, M Martinez and M Norton
Abbott, Abbott Park, IL, USA

P198 Effect of patient smoking status on CD4 count change after initiation of antiretroviral therapy
R Lodwick¹, M Johnson², C Smith¹, M Lipman², V Cambiano¹, M Tyrer², A Phillips¹ and F Lampe^1
1UCL, London, UK, ²Royal Free Hospital, London, UK

P199 Switch from Efavirenz to Etravirine improves neuropsychiatric side effects in a UK-HIV clinic cohort (Poster not yet available)
J Zhou, Z Watson, M Fisher and L Waters
BSUH, Brighton, UK

P200 An analysis of the reasons for switching combination antiretroviral (cART) regimens and associated drug wastage
D Ogden and M Pakianathan
St. George's Healthcare NHS Trust, London, UK

P201 Does shared prescribing between HIV physicians and GPs lead to more unforeseen drug interactions? (Poster not yet available)
N Gupta, V Goodall, H Loftus, C Bell, Q Younis and C Bowman
Department of Genitourinary Medicine, Royal Hallamshire Hospital, Sheffield, UK

P202 Etravirine as a first-line switch option: real world experience in one UK centre
J Shaw and S Ahmad
Withington Community Hospital, Manchester, UK

P203 Switching to maraviroc in combination with 2 NRTIs: experience in clinical practice
N Marshall, K Liu, M Macartney, A Garcia, Z Cuthbertson, L Swaden, M Tyrer and M Johnson
Royal Free Hospital NHS Trust, London, UK

P204 A question of potency? reasons for switching from atazanavir to darunavir in a London HIV cohort
J Thornhill and I Reeves
Homerton University Hospital, London, UK

P205 The outcome of switching from ritonavir boosted lopinavir to ritonavir boosted atazanavir or darunavir (Poster not yet available)
N Rockwood, G Jagjit Singh, S Mandhalia and M Nelson
Chelsea and Westminster Hospital, London, UK

P206 First line Etravirine use – can you swallow it?: real world data from one UK centre cohort
J Shaw and S Ahmad
Withington Community Hospital, Manchester, UK

P207 Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination therapy in HIV 1 patients in a resource limited setting
G Ndow, SA Diop, M Seydi, L Fortes-Déguénonvo, NM Manga, NM Dia, CD Basse, CT Ndour, M Soumare, BM Diop and PS Sow
Department of Infectious Diseases, FANN Teaching Hospital, Cheikh Anta DIOP University, Dakar, Senegal